

Clinical Dilemmas in

# Inflammatory Bowel Disease

EDITED BY

---

## **Peter Irving**

Centre for Gastroenterology  
Institute of Cell and Molecular Science  
Barts & the London, Queen Mary School of Medicine and Dentistry  
London  
UK

---

## **David Rampton**

Centre for Gastroenterology  
Institute of Cell and Molecular Science  
Barts & the London, Queen Mary School of Medicine and Dentistry  
London  
UK

---

## **Fergus Shanahan**

Department of Medicine  
National University of Ireland Cork  
Clinical Sciences Building  
Cork University Hospital  
Cork  
Eire



**Blackwell**  
Publishing



Clinical Dilemmas in

# Inflammatory Bowel Disease



Clinical Dilemmas in

# Inflammatory Bowel Disease

EDITED BY

---

## **Peter Irving**

Centre for Gastroenterology  
Institute of Cell and Molecular Science  
Barts & the London, Queen Mary School of Medicine and Dentistry  
London  
UK

---

## **David Rampton**

Centre for Gastroenterology  
Institute of Cell and Molecular Science  
Barts & the London, Queen Mary School of Medicine and Dentistry  
London  
UK

---

## **Fergus Shanahan**

Department of Medicine  
National University of Ireland Cork  
Clinical Sciences Building  
Cork University Hospital  
Cork  
Eire



**Blackwell**  
Publishing

© 2006 by Blackwell Publishing Ltd

Blackwell Publishing, Inc., 350 Main Street, Malden, Massachusetts 02148-5020, USA

Blackwell Publishing Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK

Blackwell Publishing Asia Pty Ltd, 550 Swanston Street, Carlton, Victoria 3053, Australia

The right of the Author to be identified as the Author of this Work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

First published

1 2006

Catalogue records for this title are available from the British Library and Library of Congress

ISBN-13: 978-1-4051-3377-7

ISBN-10: 1-4051-3377-5

Set in 8.75/12 pt Minion by Graphicraft Limited, Hong Kong

Printed and bound in India by Replika Press Pvt., Ltd

Commissioning Editor: Alison Brown

Editorial Assistant: Saskia van der Linden

Development Editor: Fiona Pattison

Production Controller: Kate Charman

For further information on Blackwell Publishing, visit our website:

<http://www.blackwellpublishing.com>

The publisher's policy is to use permanent paper from mills that operate a sustainable forestry policy, and which has been manufactured from pulp processed using acid-free and elementary chlorine-free practices. Furthermore, the publisher ensures that the text paper and cover board used have met acceptable environmental accreditation standards.

---

# Contents

List of Contributors, viii

Preface, xiii

## Part 1 Investigating IBD in the 21st Century

- 1** Capsule endoscopy: do we need it? 1  
*Joel E D Mawdsley & Mark Appleyard*
- 2** Pathology reports – pitfalls for the unwary, 5  
*Wilfred Weinstein*
- 3** Non-invasive diagnosis and assessment, 8  
*Alex J Di Mambro, Ana Terlevich & Chris Probert*
- 4** What is the best way to image perianal Crohn's disease? 11  
*Vikram A Sahni & Alison McLean*
- 5** Surveillance colonoscopy in UC: alternatives and ways to improve outcome, 15  
*Mark Lust & William Connell*
- 6** Abnormal liver tests – what should we do about them? 18  
*Richard Marley & Abid Suddle*

## Part 2 Medical Treatment: Making the Most of What We've Got

### 5-ASA drugs

- 7** Is monitoring necessary? 21  
*Rakesh Shah & Alastair Forbes*
- 8** Do they have a role in Crohn's disease? 25  
*Vikrant Sibartie & Brian Feagan*

### Steroids

- 9** Steroids in Crohn's: are they obsolete? 28  
*David Rampton*

### Antibiotics for Crohn's disease

- 10** Antibiotics: which, when and for how long? 32  
*Alex Kent & Jean-Frédéric Colombel*
- 11** *Mycobacterium avium paratuberculosis* in Crohn's disease: player or spectator? 36  
*Geoff Smith & Fergus Shanahan*

### Immunomodulators

- 12** TPMT testing: is it essential? 40  
*Azhar Ansari & Jeremy D Sanderson*
- 13** 6-Mercaptopurine or azathioprine? 45  
*Dermot McGovern & Simon Travis*
- 14** Thiopurines: how long should we use them for? 48  
*Alexandra Daley & Marc Lémann*
- 15** Making the most of methotrexate, 51  
*Emma Greig, John Keohane & Brian Feagan*
- 16** Cyclosporine: balancing risk and benefit, 55  
*Helena Deeney & Barney Hawthorne*

### Infliximab

- 17** Contraindications – absolute or relative? 59  
*Rakesh Chaudhary & Subrata Ghosh*
- 18** How can we prevent tuberculosis? 63  
*Sasha Beresford & David Rampton*
- 19** Dealing with infusion reactions, 67  
*Gert Van Assche, Séverine Vermeire & Paul Rutgeerts*
- 20** Use in ulcerative colitis, 70  
*Sreedhar Subramanian & Jonathan Rhodes*
- 21** Infliximab and surgery: health or hazard? 74  
*David Rampton*

### Nutritional therapy for Crohn's disease

- 22** Nutritional therapy for Crohn's disease: is it for adults? 77  
*Donald R Duerksen & Charles N Bernstein*

## Part 3 Medical Treatment: What's Round the Corner?

- 23** Trials and tribulations – interpreting clinical trials in IBD, 81  
*Elizabeth Carty & David Rampton*
- 24** Genetics – clinical and therapeutic applications, 85  
*Mark Tremelling & Miles Parkes*

- 25** Probiotics – separating science from snakeoil, 89  
*Fergus Shanahan & John Keohane*
- 26** Worms, 93  
*David Grunkemeier & R Balfour Sartor*
- 27** Smoking and nicotine – poison for Crohn’s, potion for colitis? 96  
*Brian Bressler & A Hillary Steinhart*
- 28** Heparin, 100  
*Ailsa Hart & Stuart Bloom*
- 29** Leukocytapheresis: filtering out the facts, 105  
*Peter Irving & David Rampton*
- 30** Appendectomy for ulcerative colitis – a therapeutic option? 108  
*Richard Makins & Graham Radford-Smith*
- 31** Biologic treatments in IBD, 111  
*Raymond D’Souza & James Lindsay*
- 32** Stem cell transplantation for IBD, 116  
*Paul Fortun & Christopher Hawkey*
- 33** Complementary and alternative therapy – the way forward or a step back? 121  
*Louise Langmead & David Rampton*

#### Part 4 Common Clinical Challenges: Beyond the Text Book

- 34** Functional problems, 125  
*Eamonn Quigley*
- 35** Psychological stress: something to worry about? 129  
*Joel E D Mawdsley & David Rampton*
- 36** Drugs to avoid, 133  
*Paul Collins & Jonathan Rhodes*
- 37** NSAIDs and COX-2 selective agents: cause or cure of pain in IBD? 136  
*Ingvar Bjarnason & David Scott*
- 38** Iron replacement – is it safe and effective? 139  
*Stefanie Kulnigg & Christoph Gasche*
- 39** Hepatitis B and C viruses – how do they affect management of IBD? 142  
*Graham R Foster & Alick N S Nkhoma*
- 40** Pregnancy: what drugs can we use? 146  
*Thea Thomas & Elspeth Alstead*
- 41** How to prevent growth failure in children, 150  
*Jutta Köglmeier & Nick Croft*
- 42** Predicting outcomes in severe UC, 153  
*Simon Travis*

- 43** Refractory proctitis, 156  
*Anne Ballinger & Richard Makins*
- 44** CMV co-infection – does it matter? 159  
*Daan Hommes*
- 45** Treatment of oral Crohn’s disease, 164  
*Carlo Nunes, Michael Escudier & Jeremy D Sanderson*
- 46** Pathophysiologic approach to treatment of diarrhea in Crohn’s disease, 168  
*Henry J Binder*
- 47** Short bowel, 171  
*Jeremy Nightingale*
- 48** Management of internal fistulae, 175  
*David Rampton*
- 49** What is indeterminate colitis? 179  
*Garret Cullen & Diarmuid O’Donoghue*
- 50** Pouches for indeterminate colitis? 182  
*Laura Hancock & Neil Mortensen*
- 51** Colitis-associated cancer: what’s the risk to your patients? 185  
*Jayne Eaden*
- 52** What to do with dysplasia, DALMs, and adenomas, 189  
*Matt Rutter*

#### Part 5 Managing IBD Outside the Gut

- 53** Pyoderma gangrenosum, 193  
*Ana Paula Cunha & Fernando Tavela Veloso*
- 54** Arthritides – helping the joints without harming the gut, 197  
*Horace Williams & Tim Orchard*
- 55** Prevention and treatment of osteoporosis, 201  
*Richard Makins & Juliet Compston*
- 56** Sclerosing cholangitis – what to do? 205  
*Sue Cullen & Roger Chapman*
- 57** Thromboembolic disease: an under-recognized complication? 209  
*Peter Irving & Fergus Shanahan*
- 58** Pulmonary manifestations: rare but real, 213  
*Peter Irving*

#### Part 6 Are You Sure it’s IBD?

- 59** Intestinal infections: mimics and precipitants of relapse, 217  
*Sunil Samuel & Yashwant Mahida*
- 60** Microscopic colitis, 222  
*Debbie Nathan & Peter Gibson*



- 61** Diverticular colitis, 226

*Linmarie Ludeman & Neil A Shepherd*

**Part 7 The IBD Service: Time for a Rethink?**

- 62** Outpatient services – do doctors still have a role? 229

*Mark Kelly & Andrew Robinson*

- 63** Shared care: tactical team selection, 233

*Reshma C Rakshit & John Mayberry*

- 64** Databases – are they worth the bother? 237

*Stephen L Grainger*

Index, 241

---

# List of Contributors

**Elsbeth Alstead**

Consultant Gastroenterologist  
Whipps Cross University Hospital  
Leytonstone  
London  
UK

**Azhar Ansari**

Locum Consultant Gastroenterologist  
Guy's & St Thomas' NHS Foundation Trust  
London  
UK

**Mark Appleyard**

Director of Endoscopic Services  
Royal Brisbane and Women's Hospital  
Department of Gastrointestinal Services  
Brisbane  
Australia

**Anne Ballinger**

Consultant Gastroenterologist  
Homerton University Hospital NHS  
Foundation Trust  
London  
UK

**Sasha Beresford**

IBD Specialist Pharmacist & Principal  
Pharmacist, High-Risk Medicines  
Monitoring  
Barts and The London NHS Trust  
Royal London Hospital  
Whitechapel  
London  
UK

**Charles N Bernstein**

Professor of Medicine  
University of Manitoba Inflammatory  
Bowel Disease Clinical and Research  
Center  
Winnipeg, Manitoba  
Canada

**Henry J Binder**

Professor of Medicine  
Yale University School of Medicine  
New Haven, CT  
USA

**Ingvar Bjarnason**

Professor of Digestive Diseases  
Guy's, King's, St Thomas' Medical School  
London  
UK

**Stuart Bloom**

Clinical Director  
Middlesex Hospital  
London  
UK

**Brian Bressler**

Gastroenterologist Fellow  
Mount Sinai Hospital/University Health  
Network  
University of Toronto  
Toronto, Ontario  
Canada

**Elizabeth Carty**

Consultant Gastroenterologist  
Department of Gastroenterology  
Whipps Cross University Hospital  
Leytonstone  
London  
UK

**Roger Chapman**

Department of Gastroenterology  
John Radcliffe Hospital  
Oxford  
UK

**Rakesh Chaudhary**

Clinical Research Fellow  
Department of Gastroenterology  
Hammersmith Hospital  
Imperial College  
London  
UK

**Paul Collins**

Clinical Lecturer  
Department of Medicine  
University of Liverpool  
Liverpool  
UK

**Jean-Frédéric Colombel**

Professor of Hepatogastroenterology  
Service d'Hépatogastroentérologie  
Hôpital Huriez  
France

**Juliet Compston**

Professor of Bone Metabolism  
University of Cambridge  
Department of Medicine  
Addenbrooke's Hospital  
Cambridge  
UK

**William Connell**

Director IBD Clinic  
St Vincent's Hospital  
Victoria  
Australia

**Nick Croft**

Consultant Paediatric Gastroenterologist  
Institute of Cell and Molecular Science  
Barts & the London, Queen Mary School  
of Medicine and Dentistry  
London  
UK

**Garret Cullen**

Gastroenterology Specialist Registrar  
Department of Gastroenterology  
St. Vincent's University Hospital  
Dublin 4  
Ireland

**Sue Cullen**

Consultant Gastroenterologist  
Wycombe General Hospital  
High Wycombe  
UK

**Ana Paula Cunha**

Department of Dermatovenereology  
Hospital S.João  
Porto  
Portugal

**Alexandra Daley**

Specialist Registrar in Gastroenterology  
King's College Hospital  
London  
UK

**Helena Deeney**

Specialist Registrar in Gastroenterology  
Oldchurch Hospital  
Romford  
Essex  
UK

**Alex J Di Mambro**

Clinical Science at South Bristol  
Bristol Royal Infirmary  
Bristol  
UK

**Raymond D'Souza**

Gastroenterology Registrar  
Royal London Hospital  
Whitechapel  
London  
UK

**Donald R Duerksen**

Associate Professor of Medicine  
University of Manitoba  
St. Boniface Hospital  
Winnipeg, Manitoba  
Canada

**Jayne Eaden**

Consultant Gastroenterologist  
Walsgrave Hospital  
Coventry  
UK

**Michael Escudier**

Consultant in Oral Medicine  
Guy's, Kings & St Thomas' Hospital  
London  
UK

**Brian Feagan**

Professor of Medicine  
University of Western Ontario  
Ontario, Canada

**Alastair Forbes**

Professor of Gastroenterology and Clinical  
Nutrition  
University College London  
London  
UK

**Paul Fortun**

Clinical Lecturer in Gastroenterology  
The Wolfson Digestive Diseases Centre  
University Hospital  
Nottingham  
UK

**Graham R Foster**

Professor of Hepatology  
Hepatobiliary Group  
Institute of Cell and Molecular Science  
Barts & the London, Queen Mary School of  
Medicine and Dentistry  
London  
UK

**Christoph Gasche**

Associate Professor of Medicine  
Department of Medicine  
Medical University and General  
Hospital Vienna  
Department of Medicine  
Vienna  
Austria

**Subrata Ghosh**

Professor of Gastroenterology  
Imperial College London  
Hammersmith Hospital  
London  
UK

**Peter Gibson**

Professor of Gastroenterology  
Department of Medicine  
Monash University  
Box Hill Hospital  
Victoria  
Australia

**Stephen L Grainger**

Consultant Physician and  
Gastroenterologist  
King George's Hospital  
Barking  
Essex  
UK

**Emma Greig**

Consultant Gastroenterologist  
Taunton and Somerset NHS Trust  
Taunton  
UK

**David Grunkemeier**

Division of Gastroenterology and  
Hepatology  
Multidisciplinary IBD Center  
University of North Carolina  
USA

**Laura Hancock**

Research Fellow  
Department of Colorectal Surgery  
John Radcliffe Hospital  
Oxford  
UK

**Ailsa Hart**

Gastroenterology Specialist Registrar  
University College Hospital  
London  
UK

**Christopher Hawkey**

Professor of Gastroenterology  
The Wolfson Digestive Diseases Centre  
University Hospital  
Nottingham  
UK

**Barney Hawthorne**

Consultant Gastroenterologist  
University Hospital of Wales  
Cardiff  
UK

**Daan Hommes**

Department of Gastroenterology and  
Hepatology  
Academic Medical Center  
Amsterdam  
Holland

**Peter Irving**

Centre for Gastroenterology  
Institute of Cell and Molecular Science  
Barts & the London, Queen Mary School of  
Medicine and Dentistry  
London  
UK

**Mark Kelly**

Specialist Registrar in Gastroenterology  
Hope Hospital  
Salford  
UK

**Alex Kent**

Specialist Registrar in Gastroenterology  
St. Mary's Hospital  
London  
UK

**John Keohane**

Department of Medicine and Alimentary  
Pharmabiotic Centre  
University College Cork  
National University of Ireland  
Ireland

**Jutta Köglmeier**

Specialist Registrar in Paediatric  
Gastroenterology  
Royal London Hospital  
Whitechapel  
London  
UK

**Stefanie Kulnigg**

Division of Gastroenterology and  
Hepatology  
Medical University  
Vienna  
Austria

**Louise Langmead**

Consultant Gastroenterologist  
Department of Gastroenterology  
University College London Hospitals  
London  
UK

**Marc Lémann**

Professor of Medicine  
Department of Gastroenterology  
Hôpital Saint-Louis  
Paris  
France

**James Lindsay**

Consultant Gastroenterologist  
Barts and The London NHS Trust  
Royal London Hospital  
Whitechapel  
London  
UK

**Linmarie Ludeman**

Consultant Histopathologist  
Gloucester Royal Hospital  
Gloucester  
UK

**Mark Lust**

Gastroenterology Fellow  
St. Vincent's Hospital  
Victoria  
Australia

**Yashwant Mahida**

Professor in Medicine  
Institute of Infection Immunity &  
Inflammation  
University of Nottingham  
Nottingham  
UK

**Richard Makins**

Consultant Gastroenterologist  
Department of Gastroenterology  
Whipps Cross University Hospital  
London  
UK

**Richard Marley**

Consultant Hepatologist  
Barts and The London NHS Trust  
Royal London Hospital  
Whitechapel  
London  
UK

**Joel E D Mawdsley**

Clinical Research Fellow  
Centre for Gastroenterology  
Institute of Cell and Molecular Science  
Barts & the London, Queen Mary School of  
Medicine and Dentistry  
London  
UK

**John Mayberry**

Consultant Physician  
University Hospitals of Leicester NHS Trust  
Leicester  
UK

**Dermot McGovern**

Research Fellow  
Wellcome Trust Centre for Human Genetics  
University of Oxford  
Oxford  
UK

**Alison McLean**

Consultant Radiologist  
Barts and The London NHS Trust  
Royal London Hospital  
Whitechapel  
London  
UK

**Neil Mortensen**

Professor of Colorectal Surgery  
Department of Colorectal Surgery  
John Radcliffe Hospital  
Oxford  
UK

**Debbie Nathan**

Inflammatory Bowel Disease Fellow  
Box Hill Hospital  
Victoria  
Australia

**Jeremy Nightingale**

Consultant Gastroenterologist  
Digestive Disease Centre  
Leicester Royal Infirmary  
Leicester  
UK

**Alick N S Nkhoma**

Beit Clinical Research Fellow  
Hepatobiliary Group  
Centre for Gastroenterology  
Institute of Cell and Molecular Science  
Barts & the London, Queen Mary School of  
Medicine and Dentistry  
London  
UK

**Carlo Nunes**

Clinical Research Fellow  
Gastroenterology  
Guy's & St Thomas' NHS Foundation  
Trust  
London  
UK

**Diarmuid O'Donoghue**

Consultant Gastroenterologist  
Centre for Colorectal Disease  
St. Vincent's University Hospital  
Dublin 4  
Ireland

**Tim Orchard**

Consultant Gastroenterologist  
Imperial College London  
St Mary's Hospital  
London  
UK

**Miles Parkes**

Consultant Gastroenterologist  
Department of Gastroenterology  
Addenbrooke's Hospital  
Cambridge  
UK

**Chris Probert**

Consultant and Reader in  
Gastroenterology  
Clinical Science at South Bristol  
Bristol Royal Infirmary  
Bristol  
UK

**Eamonn Quigley**

Professor of Medicine and Human  
Physiology  
Head of the Medical School  
National University of Ireland  
Cork  
Ireland

**Graham Radford-Smith**

Consultant Gastroenterologist  
Department of Gastroenterology and  
Hepatology  
Royal Brisbane and Women's Hospital  
Brisbane  
Australia

**Reshma C Rakshit**

Department of Gastroenterology  
Leicester General Hospital  
Leicester  
UK

**David Rampton**

Professor of Clinical Gastroenterology  
Centre for Gastroenterology  
Institute of Cell and Molecular Science  
Barts & the London, Queen Mary School  
of Medicine and Dentistry  
London  
UK

**Jonathan Rhodes**

Professor of Medicine  
University of Liverpool  
Liverpool  
UK

**Andrew Robinson**

Consultant Gastroenterologist  
Hope Hospital  
Salford  
UK

**Paul Rutgeerts**

Head of the IBD Research Unit  
Division of Gastroenterology  
University Hospital Gasthuisberg  
Division of Gastroenterology  
Leuven  
Belgium

**Matt Rutter**

Consultant Gastroenterologist  
University Hospital of North Tees  
Teesside  
UK

**Vikram A Sahni**

Radiology Specialist Registrar  
Barts and The London NHS Trust  
Royal London Hospital  
Whitechapel  
London  
UK

**Sunil Samuel**

Institute of Infection, Immunity &  
Inflammation  
University of Nottingham and University  
Hospital  
Nottingham  
UK

**Jeremy D Sanderson**

Consultant Gastroenterologist  
Guy's & St Thomas' NHS Foundation Trust  
London  
UK

**R Balfour Sartor**

Distinguished Professor of Medicine,  
Microbiology & Immunology  
Department of Medicine, Division of  
Gastroenterology & Hepatology  
University of North Carolina  
Chapel Hill  
USA

**David Scott**

Departments of Medicine and  
Rheumatology  
Guy's, King's, St Thomas' Medical School  
London  
UK

**Vikrant Sibartie**

Specialist Registrar in Gastroenterology  
Alimentary Pharmabiotic Centre  
Department of Medicine  
Cork University Hospital  
Cork  
Eire

**Rakesh Shah**

Specialist Registrar in Gastroenterology  
St Mark's Hospital and Academic Institute  
Harrow  
UK

**Fergus Shanahan**

Professor of Medicine and Director  
Alimentary Pharmabiotic Centre  
University College Cork  
National University of Ireland  
Cork  
Eire

**Neil A Shepherd**

Consultant Histopathologist  
Gloucestershire Royal Hospital  
Gloucester  
UK

**Geoff Smith**

Consultant Gastroenterologist  
Department of Gastroenterology  
Charing Cross Hospital  
London  
UK

**A Hillary Steinhart**

Head, Combined Division of  
Gastroenterology  
Mount Sinai Hospital/University Health  
Network  
University of Toronto  
Toronto, Ontario  
Canada

**Sreedhar Subramanian**

Clinical Research Fellow  
School of Clinical Sciences  
University of Liverpool  
Liverpool  
UK

**Abid Suddle**

Specialist Registrar in Hepatology  
Department of Gastroenterology  
Barts and The London NHS Trust  
London  
UK

**Fernando Tavarela Veloso**

Professor of Medicine  
Head of Department of Gastroenterology  
Hospital S. João  
Porto  
Portugal

**Ana Terlevich**

Clinical Science at South Bristol  
Bristol Royal Infirmary  
Bristol  
UK

**Thea Thomas**

Specialist Registrar in Gastroenterology  
Whipps Cross University Hospital  
Leytonstone  
London  
UK

**Simon Travis**

Consultant Gastroenterologist  
John Radcliffe Hospital  
Oxford  
UK

**Mark Tremelling**

Gastroenterology Specialist Registrar  
Addenbrooke's Hospital  
Cambridge  
UK

**Gert Van Assche**

Division of Gastroenterology  
University of Leuven Hospitals  
Leuven  
Belgium

**Séverine Vermeire**

Division of Gastroenterology  
University of Leuven Hospitals  
Leuven  
Belgium

**Wilfred Weinstein**

Professor of Medicine, Digestive Diseases  
Department of Medicine  
David Geffen School of Medicine a UCLA  
UCLA  
Los Angeles  
USA

**Horace Williams**

Clinical Research Fellow  
Department of Gastroenterology  
St Mary's Hospital  
Imperial College  
London  
UK

---

## Preface

In early 2004, we instigated at Barts and The London a weekly lunchtime clinical and academic IBD meeting. This is a multidisciplinary meeting, open not only to adult medical consultants and trainee gastroenterologists, but also to others including colorectal surgeons, pediatric gastroenterologists, nurses, the nutrition team, specialist pharmacists, visitors to the Unit, laboratory researchers and medical students: the average attendance is about twenty. During the meetings, we discuss patients we have encountered during the previous week who have presented difficult management problems, as well as practical day-to-day administrative issues. In addition, we decided at the outset of these meetings to ask, in rotation, attending staff each to give a 15-minute presentation on a discrete, current, controversial, important, practical, and often as yet unresolved topic relating to the care of patients with IBD. The subjects are selected by discussion between the group, and one talk is presented each week. The talks have proved extremely popular, both for the audience and the presenter, and it is out of them that the idea for this book arose.

Accordingly, this book contains a series of pithy, we hope enjoyable, sometimes provocative, but generally evidence-based articles on IBD topics which have been selected with a view to covering many of the areas that cause clinicians

difficulties in decision making. As we have deliberately chosen some controversial topics, we should perhaps point out that as editors we do not necessarily agree with all that is written here; if we did the book might prove dull. In line with its origins, some of the chapters of the book have been written in the first instance by younger gastroenterologists, prior to final touches being added by established experts.

We hope that this approach will appeal both to consultant and trainee gastroenterologists, as well as other members of the IBD team. Inevitably, the book will soon become out of date, but we hope that in the interim readers will find that it provides a useful distillation and analysis of a wide range of current management dilemmas. Indeed, we hope that you might read the odd chapter on the bus or in the train, if not in the lavatory or on the beach.

We are very grateful to all our co-authors, almost all of whom delivered their chapters on time and with minimal hassling. We are particularly grateful too to the team at Blackwell's: Alison Brown for her enthusiasm about the project when we first discussed it with her, Fiona Pattison, Mirjana Misina and Linda Bolton for all their editorial work.

PMI, DSR, FS  
March 2006





**LEARNING POINTS****Capsule endoscopy**

- Capsule endoscopy (CE) has a diagnostic yield of 40–70% in patients with suspected small bowel Crohn's disease where other investigations have been normal
- It is not yet clear whether CE provides additional information about the small bowel in patients with known Crohn's disease
- There is an emerging role for CE in differentiating Crohn's disease from indeterminate colitis
- Small bowel follow through (SBFT) is not reliable in predicting capsule retention and the role of the patency capsule is evolving
- SBFT before CE may in due course prove unnecessary in suspected small bowel Crohn's disease

**Introduction**

In addition to being the section of the gastrointestinal (GI) tract most commonly affected by Crohn's disease, the small bowel (SB) is also the most difficult region to visualize endoscopically. Wireless video capsule endoscopy (CE) is a new technology which, at least in part, overcomes this problem, by allowing complete non-invasive endoscopic imaging of the small bowel.

However, for CE to have a role in the diagnosis and management of small bowel Crohn's disease, it should fulfill several criteria: it should be safe, provide additional diagnostic information and its use should lead to clinically meaningful changes in patient management. In this chapter we discuss the limitations of other small bowel imaging

techniques, the potential uses of CE in relation to Crohn's disease and the evidence to support its use in each scenario.

**Limitations of other techniques for imaging small bowel**

Imaging of the SB has been previously limited to the radiologic techniques of small bowel follow through (SBFT), enteroclysis (double contrast small bowel examination) and computed tomography (CT) enteroclysis, and the endoscopic techniques of push enteroscopy, double balloon enteroscopy and colonoscopy with ileal intubation.

SBFT is the most common technique used to assess small bowel Crohn's but it is relatively insensitive for subtle mucosal lesions. Enteroclysis and CT enteroclysis are more invasive than SBFT, requiring the passage of a catheter into the duodenum under sedation, and several investigators have found these techniques to be no more sensitive [1]. All three techniques result in significant radiation exposure, limiting the frequency with which they should be performed.

Push enteroscopy can only view the proximal small bowel 15–160 cm beyond the ligament of Treitz and is more invasive and technically difficult than CE. Double balloon enteroscopy is an exciting new technology which has the potential to biopsy and perform therapeutic endoscopy throughout the small bowel. However, the examination is invasive, time consuming and may not examine the entire small bowel even when the procedures are performed per orally and per anally. Visualization of the terminal ileum at colonoscopy is limited both to the distal 10–15 cm of SB and to those patients in whom the terminal ileum can be successfully intubated.

**TABLE 1.1** Trials assessing the role of capsule endoscopy in the diagnosis and assessment of Crohn's disease.

Reference	N	Preceding investigation	Yield (%)	Comparator	Yield (%)
<i>Diagnosis of small bowel Crohn's</i>					
Fireman [5]	17	SBFT, EGD, colonoscopy (ileoscopy 6/17)	71	N/A	N/A
Ge [6]	20	SBFT, EGD, colonoscopy	65	N/A	N/A
Herrerias [7]	21	SBFT, EGD, colonoscopy (ileoscopy 17/21)	43	N/A	N/A
Arguelles-Arias [8]	12	SBFT, EGD, colonoscopy	75	N/A	N/A
Liangpunsakul [9]	40	SBFT, EGD, colonoscopy	7.5	CT enteroclysis	0
Eliakim [10]	35	N/A	73	SBFT CT enteroclysis	23 20
Voderholzer [11]	5	SBFT, EGD, colonoscopy	40	CT enteroclysis	40
<i>Assessing disease activity/recurrence</i>					
Buchman [12]	30	N/A	70	SBFT	67
Voderholzer [11]	8	N/A	75	CT enteroclysis	75
De Palma [15]	8	SBFT, OGD, colonoscopy, push enteroscopy	75	N/A	
Debinski [14]	10	N/A	N/A	CDAI, IBDQ, CRP	N/A
<i>Differentiating SB Crohn's from indeterminate colitis</i>					
Mow [13]	22	N/A	59	Ileoscopy	23
Whitaker [16]	7	Colonoscopy and ileoscopy	29	N/A	

CDAI, Crohn's Disease Activity Index; CRP, C-reactive protein; CT, computed tomography; IBDQ, Inflammatory Bowel Disease Questionnaire; N/A, not available; EGD, esophagogastroduodenoscopy; SBFT, small bowel follow through.

## Capsule endoscopy

The Pillcam® capsule endoscope from Given Imaging® was first used in clinical trials in 2000 and was granted Food and Drug Administration (FDA) approval in 2001 (Table 1.1). Since then it has been used in over 200 000 individuals.

Capsule endoscopy images are different from standard endoscopic images. The images are seen through intestinal content without air insufflation. Minimum standard terminology is being developed to allow consistent image description, but more validation with histology is required [2]. In a recent large randomized placebo-controlled trial looking at intestinal inflammation in patients on non-steroidal anti-inflammatory drugs, 7% of those on placebo had small bowel abnormalities [3]; these data raises the question of what constitutes a normal small bowel appearance.

The appearance of Crohn's disease at CE ranges from gross mucosal ulceration and stricturing to subtle mucosal breaks and denuded villi. A CE scoring index has been proposed along the lines of the endoscopic ones, but has not been fully validated [4].

## Diagnosis of suspected small bowel Crohn's disease

The majority of trials examining the role of CE in the management of Crohn's disease have studied the diagnostic yield of CE in patients with symptoms and features suggestive of Crohn's who have undergone normal SBFT, esophagogastroduodenoscopy (EGD) and colonoscopy (with attempted ileal intubation in some).

In prospective analyses of this nature, CE appears to provide significant additional information, with a diagnostic

yield ranging between 43% and 71% [5–8]. Furthermore, in all of these studies the positive findings at CE led to a change in management with a resulting improvement in most patients (83–100%), although treatment outcomes are not well reported.

In a retrospective analysis, the diagnostic yield was lower at 7.5% [9]. However, CE compared favorably to enteroclysis and CT enteroclysis, which were reported as normal in all the patients with positive findings at CE. In addition, all the patients responded to instigation of medical therapy.

Other studies have compared the sensitivities of CE with other techniques for diagnosing SB Crohn's disease, by performing the tests in a sequential, blinded manner. In a study comparing sequential SBFT, CT enteroclysis and CE, Eliakim *et al.* [10] found the sensitivities for Crohn's to be 23%, 20%, and 73%, respectively. Volderholzer *et al.* [11] found CE made a new diagnosis of SB Crohn's in two of five patients with unexplained diarrhea, both of whom had normal prior CT enteroclysis.

In summary, current evidence suggests that CE has a diagnostic yield of 40–70% in patients with symptoms suggestive of Crohn's disease where SBFT, OGD and colonoscopy with attempted ileal intubation have been normal. Direct comparison of diagnostic yield with enteroclysis and CT enteroclysis favors CE. The new diagnosis of Crohn's by CE has led to the institution of a beneficial new treatment regimen in most patients.

### Assessment of disease activity and recurrence

Few trials have examined whether CE is useful in assessing the SB in patients with known Crohn's. Buchman *et al.* [12] found SBFT and CE to have similar diagnostic yields at 66% and 70% in patients with suspected disease recurrence while Volderholzer *et al.* [11] found CE and CT enteroclysis each to have a diagnostic yield of 75%. Mow *et al.* [13] suggested three or more ulcers were diagnostic of Crohn's; they found CE was diagnostic in 40% and suspicious for Crohn's in 30% of patients, but did not make additional diagnoses compared with ileoscopy.

In a study to assess its potential for detection of early postoperative recurrence of Crohn's, the diagnostic yield of CE was 75% in patients with previous SB resection and suspected recurrence who had had normal SBFT, OGD, colonoscopy, and push enteroscopy [14].

Only one study has examined the role of CE in assessing

response to therapy. In this, improvements in mucosal appearance at CE were seen in 8/10 patients given infliximab [15]; these correlated with changes in Crohn's Disease Activity Index (CDAI), Inflammatory Bowel Disease Questionnaire (IBDQ) scores and C-reactive protein (CRP).

In summary, CE appears to detect recurrent small bowel Crohn's disease with a diagnostic yield of approximately 70%. However, it is not clear whether CE adds usefully to the information provided by conventional imaging techniques in this setting, nor do we yet know whether findings at CE lead to beneficial changes in management. It is therefore too early to define the role for CE in the assessment of response to therapy and of postoperative disease recurrence.

### Differentiating Crohn's disease from indeterminate colitis

In a retrospective study, CE detected SB lesions suspicious of Crohn's in 13/22 patients with a previous diagnosis of indeterminate colitis and in five led to a change in management [13]. There was, however, no comparison made to other conventional imaging techniques or to the use of antibodies to *Saccharomyces cerevisiae*/antineutrophil cytoplasmic antibody (ASCA/ANCA) serology. In a second study, CE identified lesions characteristic of CD in 2/7 patients with a diagnosis of indeterminate colitis and ongoing pain and/or diarrhea, all of whom had already undergone non-diagnostic ileoscopy [16].

### Is capsule endoscopy safe in Crohn's disease?

In all of the studies discussed above, SBFT was performed prior to CE and patients with significant stricturing were excluded from CE. CE retention occurred in 1/71 (1.4%) patients with suspected Crohn's, and in 4/80 (5%) patients with known Crohn's disease. In the trials of suspected SB Crohn's, very few patients were excluded because of abnormal radiology and radiology did not reliably prevent retention; SBFT may not therefore be required prior to CE in this setting.

Concerns regarding capsule endoscope retention have led to the development of the Patency capsule. This has the same dimensions as the Pillcam® capsule but contains only a simple tracer and is designed to disintegrate in the GI tract 40–100 hours after ingestion. In a multicenter study, the Patency capsule was passed intact in 41/80 patients with

known small bowel strictures of whom 33 then underwent conventional CE. There were no cases of capsule retention although some patients did report abdominal pain [17].

### Tolerability and capsule failure

In all the studies discussed, with the exception of patients in whom it was retained, the capsule was easily swallowed and well tolerated. Although there are no comparative preference data in these studies, in a different analysis 49/50 patients preferred CE to push enteroscopy [18].

In those studies where the data were given, the capsule failed to reach the colon before the end of its 8 hour battery life in 25/132 cases (failure rate 19%). However, in most cases, an incomplete examination did not affect diagnostic efficacy.

### Conclusions

Although the number of studies is small, current evidence suggests that there is a role for CE in the diagnosis of suspected SB Crohn's disease. However, more work is required to determine the clinical significance of the more subtle mucosal lesions and whether CE can safely be performed without prior radiology. A role for CE in assessing patients with indeterminate colitis is slowly emerging but its role in assessing disease recurrence is less clear. The Patency capsule is likely to prove useful in patients with known or suspected small bowel strictures.

### References

- Ott DJ, Chen YM, Gelfand DW, Van SF, Munitz HA. Detailed per-oral small bowel examination vs. enteroclysis. Part II: Radiographic accuracy. *Radiology* 1985; 155: 31–4.
- Korman LY. Standard terminology for capsule endoscopy. *Gastrointest Endosc Clin N Am* 2004; 14: 33–41.
- Goldstein JL, Eisen GM, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole and placebo. *Clin Gastroenterol Hepatol* 2005; 3: 133–41.
- Kornbluth A, Legani P, Lewis BS. Video Capsule Endoscopy in Inflammatory Bowel Disease: past, present, and future. *Inflam Bowel Dis* 2004; 10: 278–85.
- Fireman Z, Mahajna E, Broide E, *et al.* Diagnosing small bowel Crohn's disease with wireless capsule endoscopy. *Gut* 2003; 52: 390–2.
- Ge ZZ, Hu YB, Xiao SD. Capsule endoscopy in diagnosis of small bowel Crohn's disease. *World J Gastroenterol* 2004; 10: 1349–52.
- Herrerias JM, Caunedo A, Rodriguez-Tellez M, Pellicer F, Herrerias JM Jr. Capsule endoscopy in patients with suspected Crohn's disease and negative endoscopy. *Endoscopy* 2003; 35: 564–8.
- Arguelles-Arias F, Caunedo A, Romero J, *et al.* The value of capsule endoscopy in pediatric patients with a suspicion of Crohn's disease. *Endoscopy* 2004; 36: 869–73.
- Liangpunsakul S, Chadalawada V, Rex DK, Maglinte D, Lappas J. Wireless capsule endoscopy detects small bowel ulcers in patients with normal results from state of the art enteroclysis. *Am J Gastroenterol* 2003; 98: 1295–8.
- Eliakim R, Suissa A, Yassin K, Katz D, Fischer D. Wireless capsule video endoscopy compared to barium follow-through and computerised tomography in patients with suspected Crohn's disease: final report. *Dig Liver Dis* 2004; 36: 519–22.
- Voderholzer WA, Ortner M, Rogalla P, Beinholz J, Lochs H. Diagnostic yield of wireless capsule enteroscopy in comparison with computed tomography enteroclysis. *Endoscopy* 2003; 35: 1009–14.
- Buchman AL, Miller FH, Wallin A, Chowdhry AA, Ahn C. Videocapsule endoscopy versus barium contrast studies for the diagnosis of Crohn's disease recurrence involving the small intestine. *Am J Gastroenterol* 2004; 99: 2171–7.
- Mow WS, Lo SK, Targan SR, *et al.* Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2004; 2: 31–40.
- Debinski HS, Hooper J, Farmer C. Mucosal healing in small bowel Crohn's disease following endoscopic therapy with infliximab using the Crohn's disease capsule endoscopic index. *Proceedings of the 4th International Conference on Capsule Endoscopy, Florida, USA.* 33.
- De Palma GD, Rega M, Puziello A, *et al.* Capsule endoscopy is safe and effective after small-bowel resection. *Gastrointest Endosc* 2004; 60: 135–8.
- Whitaker DA, Hume G, Radford-Smith GL, Appleyard MN. Can capsule endoscopy help differentiate the aetiology of indeterminate colitis? *Gastrointest Endosc* 2004; 59: AB177.
- Spada C, Spera G, Riccioni ME, *et al.* Given patency system is a new diagnostic tool for verifying functional patency of the small bowel. *Proceedings of the 4th International Conference on Capsule Endoscopy, Florida, USA.* 205.
- Mylonaki M, Fritscher-Ravens A, Swain P. Wireless capsule endoscopy: a comparison with push enteroscopy in patients with gastroscopy and colonoscopy negative gastrointestinal bleeding. *Gut* 2003; 52: 1122–6.

# Part 1

# Investigating IBD in the 21st Century

## 2

## Pathology reports – pitfalls for the unwary\*

WILFRED WEINSTEIN

### LEARNING POINTS

#### Pathology reports

- Communication between pathologist and endoscopist is crucial and must be two-way
  - Do not force the pathologist to make unrealistic diagnoses or rush to judgment
  - Encourage the pathologist to avoid using hackneyed, vague, misleading, or non-actionable diagnoses
  - The endoscopist's ego strength should be sufficient to allow the pathologist to complain about poor quality biopsies, lack of clinical information, or unrealistic expectations
  - Educate each other! Send references of clinicopathologic importance in IBD to the pathologist
- Ask questions that reflect *what is possible* to determine from biopsy pathology
- Include clinical information relevant to the differential diagnosis

### Introduction

Pitfalls in pathology reports are a product of misunderstanding or miscommunication in regards to the role of biopsy in the differential diagnosis of UC and Crohn's disease. Colonic biopsy has a limited role *by itself* in the initial

evaluation, differential diagnosis, and subsequent management of inflammatory bowel disorders. However, when taken together with the history, endoscopic findings, and clinical course it may significantly help to make the case for one type of IBD rather than another [1,2].

Pitfalls occur with the too-oft practice of not providing the pathologist with an adequate history and endoscopic description, or with unrealistic expectations of what biopsy can do in management. The pathologist may not have sufficient information about the clinical manifestations and therapy of the disorders. This results in failure to be descriptive alone, when the endoscopist pressures naively or prematurely for a single diagnosis. Compounding the pitfalls is the "silence of the pathologists" who put up with no historical or endoscopic information, inadequate biopsies, and unrealistic expectations. They rarely communicate these deficiencies to the clinician [3].

### Special problems and how to minimize the risk of errors

#### Ulcerative proctitis

A biopsy is taken within a 10-cm segment of apparent diffuse inflammation in the rectum and the endoscopist asks the pathologist to "rule out ulcerative proctitis." The pathologist should never make this diagnosis unless a biopsy taken approximately 10 cm upstream is normal; that

\*UNWARY: adj: not alert to danger or deception; "seduce the unwary reader into easy acquiescence" [*The American Heritage® Dictionary of the English Language*, 4th edn, Copyright © 2000 by Houghton Mifflin Company]. Not alert: easily fooled or surprised. Heedless, gullible [from dictionary.com].

rules out proctosigmoiditis. If the proximal biopsy is normal then one can have the “ulcerative proctitis talk” with the patient, indicating that 90% of the time the disorder does not migrate proximally [4]. If the endoscopist does not consider other possible relevant causes of ulcerative proctitis when biopsies are taken, an erroneous report is inevitable; as in mucosal prolapse due to solitary rectal ulcer syndrome (SRUS), mucosal trauma from digital removal of stool, anal intercourse, sexually transmitted disease [5], and ischemic proctitis, especially after aortoiliac bypass surgery.

## Questions for the pathologist and avoiding unrealistic expectations

(Table 2.1)

### “Rule out Crohn’s disease”

This guarantees that the pathologic diagnosis will be *compatible with Crohn’s disease* because almost any histologic findings are compatible with Crohn’s disease. The solution is for the clinician to ask the pathologist if there are findings of focal inflammation in diffusely abnormal mucosa

**TABLE 2.1** Lesion descriptions, relevant medications, history, and questions for the pathologist. (After Weinstein [3])

#### Lesion description

Simple language for mucosal abnormalities: thick folds rather than hypertrophic; define friability if used, i.e. single pass petechiae or bleeding; or spontaneous petechiae or oozing. Describe what was seen rather than an interpretive term such as colitis

#### Key drugs

Type of preparation (enemas or oral)  
Current IBD treatment  
Any other immunosuppressives (e.g. after transplantation)  
Chemotherapy or radiotherapy (and when last treatment with same)  
Current or recent NSAIDs, cocaine, methamphetamine  
Current or recent antibiotics

#### History

Brief usually suffices  
Duration of diarrhea, bloody or non-bloody  
Risk factors for other disorders (see section on ulcerative proctitis)  
Underlying cardiac or vascular disease if present

#### Question for the pathologist

Be as specific as possible (see text)

NSAIDs, non-steroidal anti-inflammatory drugs.

endoscopically and if there are non-crypt cell granulomas (because granulomas next to partially degraded crypts are a feature of UC). Neither finding clinches the diagnosis of Crohn’s but the question alerts the pathologist that you are looking for more solid evidence than any small collection of inflammatory cells.

### “Rule out UC in a patient with diffusely abnormal mucosa”

My favorite question in apparent UC endoscopically is in two parts:

- 1 “It looks like UC but are there features to suggest something else?” This alerts the pathologist to look for disorders that can mimic UC, such as infectious colitis (acute self-limited) or multifocal non-crypt associated granulomas that would suggest Crohn’s disease or ischemic bowel. In endoscopically classic UC, biopsies help most when the findings do not fit.
- 2 “Are there classic signs of underlying UC?” This refers to crypt branching and subcryptal inflammatory infiltrates.

### “Is it UC or Crohn’s disease?”

Settings where that distinction is difficult to impossible in a single series of biopsies at any point in time include [2]: fulminant colitis, treated IBD, mild IBD, and new onset UC in children. A meeting of the two solitudes (clinician and pathologist) will: (i) inform the clinician about these special situations; and (ii) empower the pathologist to avoid being a collaborator in providing a definitive diagnosis when that is not possible. Fulminant or highly severe UC can be transmural and resemble Crohn’s disease. In treated UC, mild UC, and in childhood UC at presentation (even with moderate to severe symptoms), the rectum may be spared and the inflammation more severe in proximal than distal parts of the colon [2,6]. Thus, Crohn’s might be the erroneous diagnosis based upon patchiness and rectal sparing. Overall, the best time to make the distinction between UC and Crohn’s disease in adults is in the untreated state when there are active but not fulminant symptoms.

### The rush to judgment

The endoscopist should not rush to judgment, and furthermore not press the pathologist to collaborate in a rush to judgment. In patients with shorter term histories of diarrhea it may be most prudent to simply call it colitis, leave open the possibility of a self-limited disease, and treat with the usual drugs. The most common error we make is the knee

jerk label of Crohn's for any focal endoscopic involvement. Drug-induced colitis (non-steroidal anti-inflammatory drugs [NSAIDs], cocaine, methamphetamines) might be responsible for a Crohn-like or an ischemic picture [7]. Aphthous lesions from PhosphoSoda preparations occur commonly in the left colon. Ischemic colitis appearances on biopsy may be produced by infections, not just the classic *Escherichia coli* OH:157, but also others such as *Salmonella*, *Shigella*, *Clostridium difficile*, and *Campylobacter jejuni*.

#### **Biopsies taken near diverticula to look for IBD**

But the endoscopist does not tell the pathologist about the diverticulosis. A bona fide segmental colitis, only in an area of diverticula, may represent diverticular colitis and not some other focal disease such as Crohn's disease [8] (see Chapter 61).

#### **Colitis in the immunocompromised patient**

In patients with common variable immunodeficiency, undergoing chemotherapy or radiotherapy, or with human immunodeficiency virus (HIV) with low CD4 counts, and after transplantation, the main role of the endoscopist is to rule out infectious causes or endogenous changes such as chemotherapy or radiation change. UC or Crohn's disease are difficult if not impossible diagnoses to make with assurance in these settings.

### **The pathologist's vague, meaningless, or non-actionable terminology<sup>1</sup>**

Mild chronic inflammation is the greatest pandemic affecting the gastrointestinal tract. Usually these are cases with normal mucosa. Mild inflammation is present in the right colon in health, accompanied by scattered eosinophils and crypt mucus depletion, but not cryptitis. If the pathologist is not aware of this regional difference or if the endoscopist mixes right and left sided colonic biopsies into one fixative bottle, then irrelevant diagnoses may result for the unwary clinician.

Non-actionable terms unfortunately still abound. **Moderate dysplasia** in the colon is not a standard dysplasia grade, and there is no published action plan for it. **Unqualified atypia** may lead to panic and the term should not be used

unless accompanied by the adjective of **regenerative-type atypia**.

**Clinical correlation recommended.** What does this mean? Many pathologists use this as a covert term for "I'm concerned" or "I don't know what's going on histologically" to fit the clinical and/or endoscopic picture. Either sentiment is permissible. The solution is to remove the phrase and phone the clinician, or transmit any special concern in the pathology report.

**Indeterminate colitis.** This term should not be used in biopsy reports, ever. An elegant review is available for those of us who are perplexed by the diagnosis of indeterminate colitis [2].

### **Conclusion**

Histology taken at ileocolonoscopy plays a central part in the diagnosis and management of IBD. Frequent and specific communication between clinician and pathologist is the best way to minimize the risk of erroneous conclusions being reached.

### **References**

- 1 Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. *Clin Gastroenterol Hepatol* 2005; 3: 11–24.
- 2 Guindi M, Riddell RH. Indeterminate colitis. *J Clin Pathol* 2004; 57: 1233–44.
- 3 Weinstein WM. Mucosal biopsy techniques and interaction with the pathologist. *Gastrointest Endosc Clin N Am* 2000; 10: 555–72.
- 4 Ghirardi M, Nascimbeni R, Mariani PP, Di Fabio F, Salerni B. [Course and natural history of idiopathic ulcerative proctitis in adults.] *Ann Ital Chir* 2002; 73: 155–8.
- 5 Fried R, Surawicz C. Proctitis and sexually transmissible diseases of the colon. *Curr Treat Options Gastroenterol* 2003; 6: 263–70.
- 6 Bernstein CN, Shanahan F, Anton PA, Weinstein WM. Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. *Gastrointest Endosc* 1995; 42: 232–7.
- 7 Cappell MS. Colonic toxicity of administered drugs and chemicals. *Am J Gastroenterol* 2004; 99: 1175–90.
- 8 Jani N, Finkelstein S, Blumberg D, Regueiro M. Segmental colitis associated with diverticulosis. *Dig Dis Sci* 2002; 47: 1175–81.



# Part 1

## Investigating IBD in the 21st Century

### 3

## Non-invasive diagnosis and assessment

ALEX J DI MAMBRO, ANA TERLEVICH & CHRIS PROBERT

### LEARNING POINTS

#### Non-invasive diagnosis and assessment

- C-reactive protein remains an important diagnostic and monitoring tool
- Raised fecal calprotectin correlates strongly with disease activity, has been used as a screening test for IBD and may predict relapse
- The combination of perinuclear antineutrophil cytoplasmic antibody (pANCA) and antibodies to *Saccharomyces cerevisiae* (ASCA) may help differentiate ulcerative colitis from Crohn's disease, especially in children
- In the right hands, abdominal ultrasound identifies active IBD in the terminal ileum and colon
- Analysis of fecal volatiles and genetic mutations may in the future alter the way we diagnose, monitor and treat IBD.

### Introduction

Non-invasive assessment of IBD is desirable from the patient's point of view, as it is relatively painless and has few complications. However, it is also desirable from the clinical perspective: patients with chronic disease should not be exposed repeatedly to ionizing radiation, nor to endoscopic investigations, because of the potential risks from such procedures. In addition, in some parts of the world, endoscopy services are becoming over-stretched due, for example, to demands for colorectal cancer screening. In this synopsis, we discuss non-invasive methods for diagnosing and assessing IBD.

### C-reactive protein

C-reactive protein (CRP), principally produced by hepatocytes, is part of the acute phase response. It has a short half-life and is therefore a useful marker to detect and monitor disease activity in Crohn's disease [1]. A raised CRP is, of course, non-specific, but, like a raised platelet count, can point to the possibility of IBD in patients presenting to the clinic with diarrhea and/or abdominal pain. In UC the acute phase response of CRP is, for unknown reasons, only modest, and CRP is not as good a marker of disease activity except in severe relapses, when a CRP >45 mg/L during treatment indicates a high risk of colectomy (see Chapter 42) [2]. Interestingly, recent trials of biologic agents in patients with Crohn's disease have found that those patients with raised CRP tend to respond better than those without (see Chapters 23, 31).

### Plasma viscosity

Plasma viscosity is sometimes used alone, or in conjunction with CRP, to assess disease activity in IBD but is also non-specific. It has been shown to correlate well with CRP in both UC and Crohn's disease; however, it has a low sensitivity for detecting active Crohn's disease, being within the normal laboratory range in 48% of those with active disease [3].

### Calprotectin

Calprotectin is a calcium-binding protein secreted predominantly by neutrophils. Elevated fecal calprotectin levels



are found in many inflammatory diseases of the intestine [4] and have been proposed as a way of deciding which patients with diarrhea and abdominal pain need further investigation for IBD. Fecal calprotectin levels correlate strongly with IBD activity and may be used to predict relapse [5].

### Serology – pANCA and ASCA

Recent papers have shown a strong association between certain antibodies and IBD.

Perinuclear antineutrophil cytoplasmic antibody (pANCA) is found in patients with rheumatoid arthritis, systemic lupus erythematosus, microscopic polyangitis, and also in IBD. The prevalence of pANCA is increased in patients with UC (30–80%) compared with healthy controls. In comparison, pANCA is found less commonly in patients with Crohn's disease (0–20%). In UC, pANCA appears independent of disease extent and activity; however, in Crohn's disease its presence has been associated with UC-like features [6]. pANCA can be subdivided according to which perinuclear antigen antibodies are directed against. In patients with UC, the antigen may be histone 1, but antibodies are not directed against proteinase 3, myeloperoxidase, elastase, lysozyme, or cathepsin G [7].

The prevalences of IgG and IgA antibodies to *Saccharomyces cerevisiae* (ASCAs) are increased in patients with Crohn's disease compared with controls and range from 35–76% [8]. Patients who are ASCA-positive are more likely to have disease of the ileum, or ileum and colon, than patients who are ASCA-negative. Furthermore, ASCA-positive patients have also been shown to be more likely to require ileocecal resection [9].

Combining pANCA with ASCA increases specificity. For example, in UC, pANCA alone has a sensitivity and specificity of 65% and 85%, respectively; however, when combined with a negative ASCA, the sensitivity is 57% and the specificity 97% [10]. The positive predictive value (PPV) is therefore increased from 74% to 92% when the antibodies are combined.

Combined pANCA and ASCA has also been used to increase diagnostic accuracy in categorizing indeterminate colitis. One recent study showed that pANCA-positive and ASCA-negative patients with indeterminate colitis often progressed to a diagnosis of UC (PPV 64%), whereas those who were pANCA-negative and ASCA-positive were more likely to have CD (PPV 80%) [11].

Although pANCA alone is unlikely to provide the basis for a non-invasive screening test for IBD, it appears that in combination with ASCA it may have some adjuvant uses in differentiating Crohn's disease from UC, in categorizing indeterminate colitis, and possibly in determining disease pattern in Crohn's disease.

Recently, two new potential marker antibodies have been described: OmpC and I2. The low sensitivity of the antibodies to detect either Crohn's disease or ulcerative colitis means they are unlikely to have a diagnostic role [12], but they may be useful in screening for a fistulizing/stenotic phenotype with Crohn's disease as they are strongly associated with this pattern in children ( $p < 0.006$  and  $< 0.003$  for OmpC and I2, respectively [13]).

### Abdominal ultrasound

Abdominal ultrasound offers a simple, accessible, and non-invasive method of detecting and monitoring IBD (in particular Crohn's disease) and yet, at least in the UK, it is under-utilized. It has an overall accuracy of 89% in identifying active terminal ileal and colonic Crohn's disease (see Chapter 4) [14]. Doppler sonography, with or without contrast, is a newer, non-invasive method of assessing the hyperdynamic splanchnic and mesenteric blood flow that occurs in active inflammation. It can detect early mucosal and transmural inflammatory lesions. Furthermore, repeated quantification of mesenteric blood flow is claimed to enable the prediction of relapse at 6 months after steroid-induced remission [15]. (The role of magnetic resonance imaging [MRI] is discussed in Chapter 4.)

### Analysis of fecal volatiles

Some patients with IBD have observed that the gas they emit per rectum during periods of disease activity smells different to that emitted when their disease is quiescent. Recently, we have investigated the composition of gas emitted from stool samples to explore this observation further and have found that the volatile compounds of such gas are different from those found in healthy volunteers. Furthermore, the gas produced by such stool samples can be used to distinguish between UC and Crohn's disease. This observation may lead to a novel diagnostic test.

However, the technique is still under evaluation and these results need to be reproduced in larger series before its usefulness for non-invasive diagnosis or monitoring of IBD can be determined.

### Genetic mutations and IBD

The first gene to be identified as a risk factor for Crohn's disease is the *NOD2/CARD15* gene on chromosome 16 (see Chapter 24). Mutations of the gene are significantly more common in patients with Crohn's disease than in healthy controls. However, although the odds ratio is impressive, the genetic mutations are present in fewer than half of the patients studied [16,17]. At present, screening for these genes or other mutations plays no part in the diagnosis or monitoring of IBD [18].

### Conclusions

At present, CRP and plasma viscosity remain the only widely available means of non-invasive monitoring of IBD. Fecal calprotectin looks promising as a diagnostic pointer towards IBD; it has the advantage of being a test of luminal disease and is therefore unlikely to be influenced by extra-intestinal disease processes. pANCA and ASCA may have a role in distinguishing Crohn's disease from UC and, potentially, IBD from other gastrointestinal disorders. Ultrasound warrants further investigation as a non-invasive technique for both diagnosing and monitoring Crohn's disease. Analysis of fecal volatiles is still at an early stage of development but also appears promising. Genetic screening is unlikely, in the foreseeable future, to be used to make a diagnosis of IBD.

### References

- Vermeire S, Van Assche G, Rutgeerts P, *et al.* C-reactive protein as a marker for inflammatory bowel disease. *Inflamm Bowel Dis* 2004; **10**: 661–5.
- Travis SP, Farrant JM, Ricketts C, *et al.* Predicting outcome in severe ulcerative colitis. *Gut* 1996; **38**: 905–10.
- Lobo AJ, Jones SC, Juby LD, *et al.* Plasma viscosity in inflammatory bowel disease. *J Clin Pathol* 1992; **45**: 54–7.
- Johne B, Fagerhol MK, Lyberg T, *et al.* Functional and clinical aspects of the myelomonocyte protein calprotectin. *Mol Pathol* 1997; **50**: 113–23.
- Tibble JA, Sigthorsson G, Bridger S, *et al.* Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. *Gastroenterology* 2000; **119**: 15–22.
- Vasiliauskas EA, Plevy SE, Landers CJ, *et al.* Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. *Gastroenterology* 1996; **110**: 1810–9.
- Cohavy O, Bruckner D, Gordon LK, *et al.* Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. *Infect Immun* 2000; **68**: 1542–8.
- Sandborn WJ. Serological markers in inflammatory bowel disease: state of the art. *Rev Gastroenterol Disord* 2004; **4**: 167–74.
- Zholudev A, Zurakowski D, Young W, *et al.* Serologic testing with ANCA, ASCA and anto-Omp C in children and young adults with Crohn's disease and ulcerative colitis. *Am J Gastroenterol* 2004; **99**: 2235–41.
- Quinton J-F, Sendid B, Reumaux D, *et al.* Anti-*Saccharomyces cerevisiae* mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. *Gut* 1998; **42**: 788–91.
- Joossens S, Reinisch W, Vermeire S, *et al.* The value of serological markers in indeterminate colitis: a prospective follow-up study. *Gastroenterology* 2002; **122**: 1242–7.
- Elitsur Y, Lawrence Z, Tolaymat N. The diagnostic accuracy of serologic markers in children with IBD – The West Virginia experience. *Journal of Clinical Gastroenterology* 2005; **39**: 670–73.
- Dubinsky MC, Lin YC, Dutridge D, *et al.* Serum immune responses predict rapid disease progression among children with Crohn's disease: Immune responses predict disease progression. *American Journal of Gastroenterology* 2006; **101**: 360–67.
- Pascu M, Roznowski AB, Muller HP, *et al.* Clinical relevance of transabdominal ultrasonography and MRI in patients with inflammatory bowel disease of the terminal ileum and large bowel. *Inflamm Bowel Dis* 2004; **10**: 373–82.
- Ludwig D. Doppler sonography in inflammatory bowel disease. *Z Gastroenterol* 2004; **42**: 1059–65.
- Russell RK, Nimmo ER, Satsangi J. Molecular genetics of Crohn's disease. *Curr Opin Genet Dev* 2004; **14**: 264–70.
- Shaoul R, Karban A, Weiss B, *et al.* *NOD2/CARD15* mutations and presence of granulomas in paediatric and adult Crohn's disease. *Inflamm Bowel Dis* 2004; **10**: 709–14.
- Torok HP, Glas J, Lohse P, Folwaczny C. Alterations of the *CARD15/NOD2* gene and the impact on management and treatment of Crohn's disease patients. *Dig Dis* 2003; **21**: 339–45.